SG149667A1 - Extended release oral dosage composition - Google Patents

Extended release oral dosage composition

Info

Publication number
SG149667A1
SG149667A1 SG200007569-7A SG2000075697A SG149667A1 SG 149667 A1 SG149667 A1 SG 149667A1 SG 2000075697 A SG2000075697 A SG 2000075697A SG 149667 A1 SG149667 A1 SG 149667A1
Authority
SG
Singapore
Prior art keywords
oral dosage
extended release
release oral
dosage composition
pharmaceutically acceptable
Prior art date
Application number
SG200007569-7A
Other languages
English (en)
Inventor
Wing-Kee Philip Cho
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22629073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG149667(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of SG149667A1 publication Critical patent/SG149667A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200007569-7A 1999-12-20 2000-12-20 Extended release oral dosage composition SG149667A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17275299P 1999-12-20 1999-12-20

Publications (1)

Publication Number Publication Date
SG149667A1 true SG149667A1 (en) 2009-02-27

Family

ID=22629073

Family Applications (2)

Application Number Title Priority Date Filing Date
SG200007569-7A SG149667A1 (en) 1999-12-20 2000-12-20 Extended release oral dosage composition
SG2009000175A SG183573A1 (en) 1999-12-20 2000-12-20 Desloratadine solid dosage compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2009000175A SG183573A1 (en) 1999-12-20 2000-12-20 Desloratadine solid dosage compositions

Country Status (38)

Country Link
US (3) US6709676B2 (forum.php)
EP (3) EP2100600A1 (forum.php)
JP (2) JP5158919B2 (forum.php)
KR (2) KR20010062543A (forum.php)
CN (3) CN101322708A (forum.php)
AR (1) AR027034A1 (forum.php)
AT (2) ATE441404T1 (forum.php)
AU (2) AU2276801A (forum.php)
BR (1) BR0005938A (forum.php)
CA (1) CA2329172C (forum.php)
CO (1) CO5251421A1 (forum.php)
CY (3) CY1105231T1 (forum.php)
CZ (1) CZ302471B6 (forum.php)
DE (3) DE122008000001I1 (forum.php)
DK (2) DK1110543T3 (forum.php)
EC (1) ECSP003835A (forum.php)
ES (2) ES2261158T3 (forum.php)
FR (1) FR08C0004I2 (forum.php)
HU (1) HU227538B1 (forum.php)
IL (1) IL140451A (forum.php)
LU (1) LU91403I2 (forum.php)
MX (1) MXPA00012957A (forum.php)
MY (1) MY128658A (forum.php)
NL (1) NL300328I2 (forum.php)
NO (1) NO331653B1 (forum.php)
NZ (1) NZ509034A (forum.php)
PE (1) PE20010952A1 (forum.php)
PL (1) PL209401B1 (forum.php)
PT (2) PT1674084E (forum.php)
RU (1) RU2284182C9 (forum.php)
SA (2) SA06270068B1 (forum.php)
SG (2) SG149667A1 (forum.php)
SI (2) SI1110543T1 (forum.php)
SK (1) SK287105B6 (forum.php)
TR (1) TR200003788A3 (forum.php)
TW (1) TWI222885B (forum.php)
WO (1) WO2001045676A2 (forum.php)
ZA (1) ZA200007714B (forum.php)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
HU226998B1 (en) * 2000-11-23 2010-04-28 Richter Gedeon Nyrt Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PL208110B1 (pl) 2001-01-26 2011-03-31 Schering Corp Kompozycja farmaceutyczna
DE60212801T2 (de) 2001-01-26 2007-02-01 Schering Corp. Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
JP2009132734A (ja) * 2001-08-27 2009-06-18 Daiichi Sankyo Healthcare Co Ltd 抗感冒剤
JP4318899B2 (ja) * 2001-08-27 2009-08-26 第一三共ヘルスケア株式会社 抗感冒剤
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP4320217B2 (ja) * 2002-07-10 2009-08-26 剤盛堂薬品株式会社 鼻炎用経口製剤
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
TWI313598B (en) * 2002-12-18 2009-08-21 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP5137228B2 (ja) 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーション 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004080461A2 (en) * 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Stable pharmaceutical compositions of desloratadine
WO2005046650A1 (en) * 2003-11-12 2005-05-26 Glenmark Pharmaceuticals Limited Pharmaceutical formulation containing muscle relaxant and cox-ii inhibitor
EP1696881A2 (en) * 2003-12-23 2006-09-06 Sun Pharmaceutical Industries Limited Stable oral composition
US20110081415A1 (en) * 2005-03-10 2011-04-07 Taisho Pharmaceutical Co., Ltd Coating apparatus
US7927625B2 (en) * 2005-03-10 2011-04-19 Taisho Pharmaceutical Co., Ltd Sugar-coated agent
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
EP1728513A3 (en) * 2005-05-20 2007-10-31 Dr. Reddy's Laboratories, Inc. Stable desloratadine compositions
US20070004671A1 (en) * 2005-05-20 2007-01-04 Agarwal Sudeep K Stable desloratadine compositions
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
WO2007048219A2 (en) 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
US20080103746A1 (en) * 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US20110145009A1 (en) * 2005-11-30 2011-06-16 Jung Edward K Y Methods and systems related to transmission of nutraceutical associatd information
US20080033763A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to receiving nutraceutical associated information
US20080114577A1 (en) * 2005-11-30 2008-05-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems associated with nutraceutical related assays
US20080052114A1 (en) * 2005-11-30 2008-02-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods related to nutraceuticals
US7927787B2 (en) * 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8340944B2 (en) * 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070124218A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized nutraceutical selection and packaging
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070289258A1 (en) * 2006-06-14 2007-12-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Individualized pharmaceutical selection and packaging
US10296720B2 (en) * 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20070174128A1 (en) * 2005-11-30 2007-07-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20080004905A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
EP1988893A4 (en) * 2006-02-22 2010-05-26 Orchid Chemicals & Pharm Ltd FORMULATION CONTAINING DESLORATADINE STABILIZED USING CYCLODEXTRIN
CA2541045A1 (en) * 2006-03-24 2007-09-24 Pharmascience Inc. A descarbonylethoxyloratadine containing pharmaceutical composition
NZ573173A (en) 2006-06-01 2012-03-30 Msd Consumer Care Inc Phenylephrine pharmaceutical formulation and compositions for colonic absorption
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
US20070281020A1 (en) * 2006-06-01 2007-12-06 Ulloa Sergio R Pharmaceutical compositions for sustained release of phenylephrine
PE20080313A1 (es) * 2006-06-01 2008-04-10 Schering Corp Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas
US7718649B1 (en) * 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US20080299186A1 (en) * 2007-06-01 2008-12-04 Schering-Plough Healthcare Products, Inc. Coatings for applying substances onto substrate carrier
TWI400042B (zh) * 2007-06-08 2013-07-01 Tci Co Ltd 食品錠劑
WO2009049405A1 (en) 2007-10-16 2009-04-23 Labopharm Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
KR20100121463A (ko) 2007-12-17 2010-11-17 라보팜 인코포레이트 오용 예방적 방출 제어형 제제
CN102316857A (zh) 2008-12-16 2012-01-11 莱博法姆公司 防止误用的控释配方
CA2836769C (en) * 2011-05-04 2018-11-13 Intellikine, Llc The combination of paclitaxel and an mtor inhibitor for the treatment of a proliferative disorder
BR102012030828A2 (pt) 2012-12-03 2014-09-16 Ems Sa Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso
US10576041B2 (en) 2016-09-26 2020-03-03 The Procter & Gamble Company Extended relief dosage form
US10463656B2 (en) 2017-01-05 2019-11-05 Iowa State University Research Foundation, Inc. Methods and compositions for prevention of feedlot bovine respiratory disease
CN109966254B (zh) * 2017-12-28 2021-06-01 广州医药研究总院有限公司 复方地氯伪麻缓释小丸及其制备方法
CN108578406A (zh) * 2018-04-18 2018-09-28 曹建华 一种用于过敏性鼻炎治疗的组合物
US11806320B2 (en) * 2020-02-19 2023-11-07 Endo Ventures Limited Isoproterenol compositions and methods
CN113230235B (zh) * 2021-04-15 2022-11-11 海南普利制药股份有限公司 含地氯雷他定的复方缓释胶囊及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396404A1 (en) * 1989-05-03 1990-11-07 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
EP0577957A1 (en) * 1992-05-22 1994-01-12 J. URIACH & CIA. S.A. 8-Chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
WO1999062516A1 (en) * 1998-06-01 1999-12-09 Schering Corporation A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3940485A (en) 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4008796A (en) 1974-03-26 1977-02-22 General Concrete Of Canada Limited Control method for feeding items on a conveyor
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
HU194864B (en) 1984-02-15 1988-03-28 Schering Corp Process for production of 8-chlor-6,11-dihydro-11-(4-piperidilidene)-5h-benzo (5,6)-cyclo-hepta (1,2-b) pyridine and its salts
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
SE8404467D0 (sv) 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4804666A (en) 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
JPS6396126A (ja) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4777170A (en) 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
GB8707421D0 (en) 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4863931A (en) 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5019591A (en) 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
ZA914764B (en) 1990-06-22 1992-03-25 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use
JPH06504772A (ja) 1990-12-18 1994-06-02 ザ　ウエルカム　ファウンデーション　リミテッド 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤
PT100502A (pt) 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
JP2646972B2 (ja) 1993-11-01 1997-08-27 日本電気株式会社 多ビットメモリ
DE4442999A1 (de) 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US7211582B1 (en) * 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) * 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
CZ150999A3 (cs) * 1996-10-31 1999-10-13 Schering Corporation Farmaceutický prostředek pro léčbu astmatu obsahující loratadin a dekongestant
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
US5900421A (en) 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6506767B1 (en) 1997-07-02 2003-01-14 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine
BR9812001A (pt) * 1997-08-26 2000-09-26 Hoechst Marion Roussel Inc Composição farmacêutica para combinação de descongestionante piperidinoalcanol
US6270796B1 (en) 1997-10-29 2001-08-07 Robert E. Weinstein Antihistamine/decongestant regimens for treating rhinitis
ATE432075T1 (de) * 1998-07-10 2009-06-15 Schering Corp Orale zusammensetzungen mit 8-chloro-6,11-dihydro-11-(4-piperidylene)-5h-be zoä5,6ü-cyclo-heptaä1,2-büpyridin
US6423721B1 (en) * 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6051585A (en) 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6100274A (en) 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
WO2001056571A1 (en) * 2000-02-03 2001-08-09 Schering Corporation Treating allergic and inflammatory conditions
ES2222370T3 (es) * 2000-05-19 2005-02-01 Alcon Inc. Derivados de disulfuro de anilina para tratar enfermedades alergicas.
US6599913B1 (en) 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions
US6679463B1 (en) * 2003-06-11 2004-01-20 Kye Systems Corp. Support with multi-stage clamping mechanism
EP1696881A2 (en) * 2003-12-23 2006-09-06 Sun Pharmaceutical Industries Limited Stable oral composition
AU2005263958B2 (en) * 2004-07-16 2011-04-14 Cipla Limited Anti-histaminic composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396404A1 (en) * 1989-05-03 1990-11-07 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
EP0577957A1 (en) * 1992-05-22 1994-01-12 J. URIACH & CIA. S.A. 8-Chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
WO1999062516A1 (en) * 1998-06-01 1999-12-09 Schering Corporation A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer

Also Published As

Publication number Publication date
JP2008081509A (ja) 2008-04-10
FR08C0004I2 (fr) 2009-01-15
HUP0004989A2 (hu) 2004-05-28
SA06270068B1 (ar) 2009-12-23
KR20080044214A (ko) 2008-05-20
PT1110543E (pt) 2006-08-31
HK1090840A1 (en) 2007-01-05
ECSP003835A (es) 2002-02-25
TR200003788A2 (tr) 2001-07-23
JP2001206846A (ja) 2001-07-31
NZ509034A (en) 2002-09-27
SI1674084T1 (sl) 2010-01-29
PE20010952A1 (es) 2001-09-25
KR20010062543A (ko) 2001-07-07
DK1674084T3 (da) 2009-12-14
TWI222885B (en) 2004-11-01
CO5251421A1 (es) 2003-02-28
HK1034452A1 (en) 2001-10-26
US8187630B2 (en) 2012-05-29
EP1110543A3 (en) 2001-08-29
ES2261158T3 (es) 2006-11-16
BR0005938A (pt) 2001-11-27
ATE441404T1 (de) 2009-09-15
PL209401B1 (pl) 2011-08-31
FR08C0004I1 (forum.php) 2008-03-21
PL344714A1 (en) 2001-07-02
CN101134038B (zh) 2013-11-06
EP1110543A2 (en) 2001-06-27
CY1105231T1 (el) 2010-03-03
RU2284182C9 (ru) 2007-11-20
CA2329172C (en) 2005-10-25
HUP0004989A3 (en) 2008-04-28
NL300328I2 (nl) 2008-07-01
US6709676B2 (en) 2004-03-23
HU0004989D0 (forum.php) 2001-02-28
CN101134038A (zh) 2008-03-05
EP1674084B1 (en) 2009-09-02
CZ302471B6 (cs) 2011-06-08
SK19662000A3 (sk) 2001-09-11
CZ20004813A3 (cs) 2001-08-15
CN100415223C (zh) 2008-09-03
MY128658A (en) 2007-02-28
ES2330873T3 (es) 2009-12-16
AU2276801A (en) 2001-07-03
NO20006503L (no) 2001-06-21
NO20006503D0 (no) 2000-12-20
SA01210740A (ar) 2005-12-03
US7618649B2 (en) 2009-11-17
NO331653B1 (no) 2012-02-13
DK1110543T3 (da) 2006-09-18
AU777419B2 (en) 2004-10-14
IL140451A0 (en) 2002-02-10
US20040097536A1 (en) 2004-05-20
DE122008000001I1 (de) 2008-04-17
US20030031713A1 (en) 2003-02-13
CY1109636T1 (el) 2014-08-13
LU91403I2 (fr) 2008-02-21
EP1110543B1 (en) 2006-06-14
SI1110543T1 (sl) 2006-10-31
PT1674084E (pt) 2009-10-19
EP2100600A1 (en) 2009-09-16
RU2284182C2 (ru) 2006-09-27
SK287105B6 (sk) 2009-12-07
EP1674084A2 (en) 2006-06-28
CN1302605A (zh) 2001-07-11
SA01210740B1 (ar) 2006-10-31
CN101322708A (zh) 2008-12-17
HU227538B1 (en) 2011-08-29
ZA200007714B (en) 2001-08-16
CY2007031I1 (el) 2009-11-04
SG183573A1 (en) 2012-09-27
WO2001045676A3 (en) 2002-01-03
ATE329584T1 (de) 2006-07-15
NL300328I1 (nl) 2008-03-03
EP1674084A3 (en) 2006-07-05
CA2329172A1 (en) 2001-06-20
MXPA00012957A (es) 2003-06-19
TR200003788A3 (tr) 2001-07-23
JP5158919B2 (ja) 2013-03-06
AU7244200A (en) 2001-06-21
DE60028710T2 (de) 2007-06-14
DE60028710D1 (de) 2006-07-27
AR027034A1 (es) 2003-03-12
CY2007031I2 (el) 2009-11-04
WO2001045676A2 (en) 2001-06-28
DE60042904D1 (de) 2009-10-15
US20100021542A1 (en) 2010-01-28
IL140451A (en) 2011-11-30

Similar Documents

Publication Publication Date Title
SG149667A1 (en) Extended release oral dosage composition
EP1566174A3 (en) Flash-melt oral dosage formulation
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
CA2131350A1 (en) Sustained release drug formulation containing a tramadol salt
NZ507566A (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
CA2342340A1 (en) New sustained release oral formulations
GR3030614T3 (en) INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17-g(b)-OESTRADIOL PRECURSORS
AU4425496A (en) Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
AU2623600A (en) Compact dosage unit for buccal administration of a pharmacologically active agent
ZA973190B (en) Fast melting oral dosage form.
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
BG104620A (en) Oral pharmaceutical extended release dosage form
HUP0004966A2 (en) Pharmaceutical composition for oral administration in the form of matrix tablet enabling the prolonged release of trimetazidine
IL127572A (en) Pharmaceutical composition and medicament for nasal administration
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
MY127350A (en) Flash-melt oral dose formulations
EG23994A (en) Pharmaceutical compositions for oral and topical administration
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
ZA987723B (en) Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and a medicament for the treatment of cardiovascular diseases
IL136142A0 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
IL112745A0 (en) Formulations for orally administered pharmaceutical agents
PL348202A1 (en) Pharmaceutically active composition and dispensing device
CA2280685A1 (en) A medicament against infertility and for increasing fertility
HK1031822A (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
GB9806139D0 (en) Combined aspirin and destrogenic compound pharmaceutical formulation for oral contraception or hormone replacement therapy